484 related articles for article (PubMed ID: 20159824)
1. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
2. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Danila DC; Morris MJ; de Bono JS; Ryan CJ; Denmeade SR; Smith MR; Taplin ME; Bubley GJ; Kheoh T; Haqq C; Molina A; Anand A; Koscuiszka M; Larson SM; Schwartz LH; Fleisher M; Scher HI
J Clin Oncol; 2010 Mar; 28(9):1496-501. PubMed ID: 20159814
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
7. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G; Reid AH; Yap TA; Raynaud F; Dowsett M; Settatree S; Barrett M; Parker C; Martins V; Folkerd E; Clark J; Cooper CS; Kaye SB; Dearnaley D; Lee G; de Bono JS
J Clin Oncol; 2008 Oct; 26(28):4563-71. PubMed ID: 18645193
[TBL] [Abstract][Full Text] [Related]
9. Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.
Pal SK; Twardowski P; Josephson DY
Maturitas; 2009 Oct; 64(2):61-6. PubMed ID: 19733987
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
13. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone in prostate cancer: a new angle to an old problem.
Stein MN; Goodin S; Dipaola RS
Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
17. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.
Ryan CJ; Shah S; Efstathiou E; Smith MR; Taplin ME; Bubley GJ; Logothetis CJ; Kheoh T; Kilian C; Haqq CM; Molina A; Small EJ
Clin Cancer Res; 2011 Jul; 17(14):4854-61. PubMed ID: 21632851
[TBL] [Abstract][Full Text] [Related]
19. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
Kim W; Zhang L; Wilton JH; Fetterly G; Mohler JL; Weinberg V; Morse A; Szmulewitz RZ; Friedlander TW; Fong L; Lin AM; Harzstark AL; Molina A; Small EJ; Ryan CJ
Clin Cancer Res; 2014 Dec; 20(24):6269-76. PubMed ID: 25336698
[TBL] [Abstract][Full Text] [Related]
20. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
